Αρχική World News Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML World News Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML Από Ogkologos - 14 Σεπτεμβρίου, 2026 132 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PARADIGM study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ AI for early cancer detection: where are we now? Could virtual reality become a reality in cancer supportive care? EMA recommends granting a marketing authorisation for daraxonrasib MOST POPULAR Metastasis Likely Caused by Lack of Oxygen in Cancerous Tumors, Study... 14 Σεπτεμβρίου, 2020 Mom Warns Others After Little Girl’s Skin Blisters From ‘Margarita Burn’ 31 Ιουλίου, 2019 Encouraging Single-Agent Antitumour Activity of Divarasib Across KRAS G12C-positive Tumours 5 Σεπτεμβρίου, 2023 9/11 Firefighter Dies Of Cancer From Working At Ground Zero 23 Ιουλίου, 2019 Φόρτωση περισσοτέρων HOT NEWS What Is Intuitive Eating and How Can It Help During Cancer? Changing the landscape of children’s cancer treatment Study Suggests that Cancer Patients Who Eat Peanuts Frequently May Be... Metastatic Breast Cancer: ESMO Living Guideline